US88322Q1085 - Common Stock
TG THERAPEUTICS INC
NASDAQ:TGTX (12/24/2024, 7:41:00 PM)
After market: 32.8058 +0.65 (+2.01%)32.16
-0.1 (-0.31%)
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 319 full-time employees. The firm is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
TG THERAPEUTICS INC
3020 Carrington Mill Blvd., Suite 475
Morrisville NORTH CAROLINA 10014
P: 18775758489
CEO: Michael S. Weiss
Employees: 300
Website: https://www.tgtherapeutics.com/
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET...
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast...
A Fed rate cut and a slew of big earnings reports filled out a busy week.
The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.
Here you can normally see the latest stock twits on TGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: